Bayesian Capital Management, LP Arrowhead Pharmaceuticals, Inc. Transaction History

Bayesian Capital Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$27.21 - $39.48 $688,494 - $998,962	25,303 New	25,303 $723,000
Q1 2023 May 15, 2023	BUY	$23.68 - $38.51 $773,909 - $1.26 Million	32,682 New	32,682 $830,000
Q4 2020 Feb 12, 2021	SELL	$43.82 - $85.37 $305,250 - $594,687	-6,966 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$33.21 - $51.27 $231,340 - $357,146	6,966 New	6,966 $300,000
Q2 2020 Aug 14, 2020	SELL	$26.12 - $43.27 $296,044 - $490,422	-11,334 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$20.56 - $63.12 $133,640 - $410,280	6,500 Added 134.46%	11,334 $326,000
Q4 2019 Feb 14, 2020	BUY	$28.14 - $73.01 $136,028 - $352,930	4,834 New	4,834 $307,000

305

95.9M

523K

493K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.